Reach FDA 21 CFR Part 50 + 56 — Human Subject Protection readiness without rebuilding your policy programme
FDA 21 CFR Part 50 (Protection of Human Subjects) + Part 56 (Institutional Review Boards) govern the protection of human subjects in FDA-regulated clinical investigations — operationalising the Belmont Report principles. Part 50 requires informed consent + (for emergency research) exception conditions; Part 56 requires IRB review + approval + continuing review. Aligned with the Common Rule (45 CFR §46 Subpart A) since the 2018 revisions, with FDA-specific differences (e.g., no broad consent option, expanded children's research provisions). Inspections by FDA BIMO program. Quick Policy maps FDA 21 CFR Part 50 + 56 — Human Subject Protection into the policy families, controls, and evidence your team needs - and keeps it current between audits.
Standards assurance
How Quick Policy verifies against FDA 21 CFR Part 50 + 56 — Human Subject Protection
Every policy Quick Policy generates is scored against FDA 21 CFR Part 50 + 56 — Human Subject Protection's pass mark, with a PASS, WARN, or FAIL verdict and plain-English guidance on what to fix when it falls short.
A monthly automated audit re-checks coverage against this standard, so drift is caught between scheduled reviews rather than at the next one.
Audit-ready exports bundle the scored policies, gap guidance, and review history into one evidence pack when it is time to show your work.
FDA 21 CFR Part 50 + 56 — Human Subject Protection quick answer
Standard facts
Framework: FDA_HUMAN_SUBJECT
Authority: US Food and Drug Administration (FDA / BIMO)
Jurisdiction: US
Why FDA 21 CFR Part 50 + 56 — Human Subject Protection matters for your operating model
FDA 21 CFR Part 50 + 56 — Human Subject Protection doesn't just dictate document templates - it shapes which controls auditors test, what evidence they ask for, and which gaps surface first during diligence. Getting it wrong creates renewal slippage, audit findings, and stalled customer deals.
- • Issued by US Food and Drug Administration (FDA / BIMO) and primarily enforced in US.
- • Directly shapes policy families including Clinical Trials, Ethics — these are the artefacts assessors open first.
- • Common artifacts include Policy.
- • Obligation model: Mandatory In Scope — meaning you need defensible reasoning for in-scope vs out-of-scope decisions, not just signed policies.
How Quick Policy helps you stand up FDA 21 CFR Part 50 + 56 — Human Subject Protection
The platform turns FDA 21 CFR Part 50 + 56 — Human Subject Protection from a PDF of requirements into a live operating model - policies, training, evidence, and audit-export packs that update in lock-step when the standard or your business changes.
- • Adopt FDA 21 CFR Part 50 + 56 — Human Subject Protection once and Quick Policy seeds the right policy families (Clinical Trials, Ethics) with applicability rationale your auditor can follow.
- • Common artifacts include Policy.
- • Review cadence is enforced at ~365 days so policies don't silently expire ahead of recertification.
- • Standard updates (FDA 21 CFR Part 50 + 56 — Human Subject Protection revisions, errata, regulator guidance) trigger an applicability re-check across your active policies - not a full rewrite.
Policy families commonly involved
Recommended artifacts and context
Industry tags: LIFE_SCIENCES
Obligation model: Mandatory In Scope
Coverage depth: Profile
How Quick Policy puts FDA 21 CFR Part 50 + 56 — Human Subject Protection into practice
Turn standards context into drafting, review, training, and evidence workflows that are easier to maintain over time.
Capture Core Profile
Admins complete adaptive onboarding to establish operating model, risk posture, and compliance objectives.
Determine Applicable Standards
Standards applicability ranks obligations by industry, geography, services, and data profile.
Generate and Harmonise Policy
Three-pass generation drafts, repairs contradictions, and validates coverage before reviewer handoff.
Review, Approve, and Sign Off
Approvers validate policy language, mappings, and obligations, then publish through a sign-off chain that tracks every person against every policy on one exportable compliance matrix.
Need adjacent guidance?
Use these pages for broader platform, industry, or buying context around FDA 21 CFR Part 50 + 56 — Human Subject Protection.
Get FDA 21 CFR Part 50 + 56 — Human Subject Protection-ready without the consultant invoice
Start a guided preview - no card, no sales call. See how FDA 21 CFR Part 50 + 56 — Human Subject Protection applies to you and draft your first aligned policy preview before you pick a plan; publishing and audit-ready exports unlock after checkout.
FDA 21 CFR Part 50 + 56 — Human Subject Protection FAQs
What does FDA 21 CFR Part 50 + 56 — Human Subject Protection actually require?
FDA 21 CFR Part 50 (Protection of Human Subjects) + Part 56 (Institutional Review Boards) govern the protection of human subjects in FDA-regulated clinical investigations — operationalising the Belmont Report principles. Part 50 requires informed consent + (for emergency research) exception conditions; Part 56 requires IRB review + approval + continuing review. Aligned with the Common Rule (45 CFR §46 Subpart A) since the 2018 revisions, with FDA-specific differences (e.g., no broad consent option, expanded children's research provisions). Inspections by FDA BIMO program. In practice that means the policies, controls, and evidence around Clinical Trials, Ethics need to be authored, owned, tested, and producible on demand. Quick Policy maps each requirement to a policy section and evidence type so you can show coverage clause-by-clause.
How does Quick Policy accelerate FDA 21 CFR Part 50 + 56 — Human Subject Protection adoption?
When you adopt FDA 21 CFR Part 50 + 56 — Human Subject Protection, Quick Policy auto-recommends the policy families, applicability decisions, and evidence types that align to it. Drafting uses FDA 21 CFR Part 50 + 56 — Human Subject Protection-aware AI prompts so drafts arrive pre-mapped to clauses - not as blank templates you have to wire up afterwards.
Will adopting FDA 21 CFR Part 50 + 56 — Human Subject Protection in Quick Policy replace our auditor or assessor?
No - Quick Policy gets you to a defensible operating programme that an assessor or auditor can review against FDA 21 CFR Part 50 + 56 — Human Subject Protection. We provide the policy artefacts, evidence trails, and exports they need; certification, attestation, or audit opinion remains the assessor's role.
What if FDA 21 CFR Part 50 + 56 — Human Subject Protection is updated mid-cycle?
Standard revisions, errata, and regulator guidance feed back into the applicability engine. You get a watchdog alert with the affected policies, recommended next actions, and a one-click re-baseline against the new version — without scrapping the work already in place.